20/20 HealthCare Partners

20/20 HealthCare Partners LLC is a venture capital and private equity firm specializing in investments in growth equity, recapitalizations of established companies, and buyout. The firm seeks to invest in incubation, pre-seed, early stage, mature, mid venture, late venture, emerging growth and middle market companies. The firm seeks to invest in of technology and life science innovation with the focus on biotechnology and pharmaceuticals, healthcare industry software, diagnostic imaging, medical devices, and healthcare IT. It may also lead investments working with private investors and hedge funds, to execute larger transactions; provide assistance with strategic alliances and company mergers, and operational support and Board of Director level advice and other strategic consulting. 20/20 HealthCare Partners LLC is based in Auburndale, Massachusetts.

Hillel Bachrach

Managing Partner

Christine Bunt


Jonathan Fleming

Advisory Board


Martin D. Mann


11 past transactions

Coagulo Medical Technologies

Venture Round in 2020
Coagulo Medical Technologies, Inc. develops testing systems that detects, identifies, and quantifies the effect of all anticoagulants in whole blood and communicates actionable results to healthcare providers. The company is based in Auburndale, Massachusetts.


Venture Round in 2013
physIQ has developed a personalized physiology analytic platform (PPA) for use in both the regulated healthcare market as well as the unregulated health and fitness market. The technology is designed to detect subtle changes in vital signs and other health indicators to help clinicians manage patients with chronic illness, and to help consumers track their own health and fitness levels. The key differentiator between the physIQ platform and other technologies is that it constructs a personalized baseline norm for each person monitored, rather than simple trending or comparison to population-based statistics. Our technology can also be embedded into patient monitoring devices from other manufacturers who are seeking to design "smarter" products.


Series C in 2021
Variantyx Inc. provides whole genome sequencing based diagnostic testing platform. It performs diagnostic testing for rare disorders with genome unity, personal genome screening for healthy individuals with genomic inform, and Next Generation Sequencing (NGS) analysis and reporting for laboratories with genomic intelligence. Variantyx Inc. was founded in 2014 and is headquartered in Framingham, Massachusetts.
SQZ Biotech is a developer of a cell engineering technology designed to deliver a diverse set of materials into patient cells. It is a privately held company that develops cellular therapies for multiple indications using the proprietary CellSqueeze technology. Through internal research programs and external partnerships, SQZ’s unique cell engineering capabilities are being used to develop a new generation of cell therapies by engineering the immune system both through immune activation and immune suppression for a wide range of clinical challenges.

EightSpokes, Inc.

Venture Round in 2015
EightSpokes, Inc. offers a SaaS platform that solves the problem of launch delays by implementing the Enlighten launch management software to replace the manual planning, coordination, and communication problems that occur. The company was incorporated in 2012 and is based in Lexington, Massachusetts.


Series A in 2012
A solar panel that tracks the sun throughout the day produces up to 30% more electricity than one that does not. Solar project developers install single-axis tracking for most utility-scale sites, balancing upfront costs versus electricity revenues to maximize rates of return. QBotix disrupts today's cost curve of fixed-tilt, single-axis tracking, and dual-axis tracking with an innovative tracking solution that offers dual-axis tracking at single-axis price. This reduces the levelized cost of energy by 10-20% while providing the added benefit of higher reliability and system intelligence.


Venture Round in 2011
Zixi is the leading enabler of flawless broadcast quality HDTV over the Internet. Broadcasters, enterprises and video-on-demand services use Zixi to enrich user experience, create new services and significantly reduce costs. Zixi enables the delivery of live and on-demand HD video content over the Internet in real time and with unprecedented quality. The technology is applicable for multi-media delivery and consumption across a spectrum of industries.


Venture Round in 2020
XRHealth is a medical device company that develops XR (VR\AR) therapeutic platform. The XRHealth Platform combines medical applications with advanced data analytics and remote monitoring, providing a comprehensive solution for clinicians and patients and pharma companies. The XRHealth Platform collects and analyzes patient interactions with virtual objects in virtual environments. AI cloud computing algorithms let us deliver an enhanced experience and real-time data analytics that can be used in clinics and in the home. With our technology, patients can analyze and quantify their own performance and track their own improvement over time. XRHealth is the first Certified Virtual Reality (VR) Medical Company to develop FDA/CE Registered Medical Applications. Our products focus on motor, cognitive, physical, psychological, postural ability and pain assessment and treatment.

Velocomp LLC

Venture Round in 2011
Velocomp is a sports technology company that offers a range of power measurement tools for bicycles worldwide. Its products include iSport, a wireless cycling computer and power meter; iPro, a product which helps in tracking progress and analyzing rides; iBike POWERHOUSE, a cycling computer that automatically adjusts to exercise goals; iAero, a product which helps in power and wind tunnel measurements; iDash CC, a cycling computer; iDash CC Deluxe, a fitness computer; iDash +Power, a dashboard for training and fitness; and protective bicycle cases and mounts for iPhone and iPod touch.

EnClear Therapies, Inc.

Series A in 2020
EnClear Therapies, Inc. develops device-based therapies for the treatment of neurodegenerative disease. The company delivers and monitors cerebrospinal fluids (CSF). The company’s therapeutic platform focuses on removing toxic proteins from the CSF. Its products are targeted for patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP) and other conditions related to the central nervous system (CNS). EnClear Therapies, Inc. was incorporated in 2018 and is based in Newburyport, Massachusetts.

Verseau Therapeutics, Inc.

Venture Round in 2019
Verseau is creating a new class of therapeutics, macrophage checkpoint modulators, to benefit patients with cancer, immune and inflammatory diseases. The company's modulators identify novel targets and develop therapies that shift macrophages between immune activators and silencers in disease, enabling physicians to benefit patients from immunotherapy.